Targeting GLS, a key enzyme in glutamine metabolism, through genetic knockdown or pharmacological inhibition (e.g., using CB-839) can induce glutamine deprivation and ROS accumulation in cancer cells, subsequently triggering ferroptosis in ovarian cancer cells [55]. The gene discussed is GLS; the disease is ovarian carcinoma.